Serum exocrine pancreas enzymes are biomarkers of immunotherapy response in new-onset type 1 diabetes

IntroductionThe immune-mediated destruction of insulin-producing β-cells characterizes type 1 diabetes. Nevertheless, exocrine pancreatic enzymes, including amylase, lipase, and trypsin, are also significantly reduced in type 1 diabetes. With an immunotherapy now approved to treat early-stage type 1...

Full description

Saved in:

Bibliographic Details
Main Authors:	Brittany Sorensen Bruggeman, Savanna Gornisiewicz, Rhonda Bacher, Kieran McGrail, Martha Campbell-Thompson, Clive Wasserfall, Laura M. Jacobsen, Mark Atkinson, Michael J. Haller, Desmond A. Schatz
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Endocrinology
Subjects:	type 1 diabetes exocrine pancreas immunotherapy thymoglobulin granulocyte colony stimulating factor pancreatic alpha-amylase
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1497373/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Serum exocrine pancreas enzymes are biomarkers of immunotherapy response in new-onset type 1 diabetes

Similar Items